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Background: Hyperglycemia appears to play a significant role on the inflammatory cytokines production.
Beta2-microglobulin (beta2M) is accumulated in the circulation of dialysis patients. We studied the relationship
between glycemic control defined by glucose serum concentrations and insulin resistance, beta2M and markers of
inflammation in patients on renal replacement therapies with or/and without diabetes mellitus.
Methods: We enrolled 96 dialyzed patients, 62 males and 34 females. The treatment modalities which were
applied were : regular hemodialysis (HD, n = 34), predilution hemodiafiltration (HDF, n = 42) and peritoneal dialysis
(PD, n = 20). Dialysis adequacy was defined by Kt/V for urea.Beta2M and insulin serum concentrations were
measured by radioimmunoassays. hsCRP and TNF-α serum concentrations were measured by ELISA. Insulin resistance
was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR).We examined the association
of elevated serum glucose with inflammatory factors and we built a multivariable model to investigate if glucose could
be a potential determinant of beta2M serum levels.
Results: Serum glucose was positively correlated with beta2M and TNF-α (r = 0.320, p = 0.002 and r = 0.215, p = 0.03
respectively).We observed significant association between the patients with higher serum glucose concentrations and the
patients with greater beta2Μ concentrations (x2 = 4.44, p = 0.03). Multivariable model showed that glucose acts as a
significant independent determinant of beta2M adjusting for age, gender, dialysis modality and metabolic acidosis status.
Conclusions: The elevated glucose concentrations were positively associated with both, greater beta2M serum
concentrations and up-regulated inflammatory procedure in dialysis patients with or/and without diabetes mellitus.
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Beta2-microglobulin (beta2M), which is one of the major
histocompatibility complex class I molecules, is accumu-
lated in the circulation of dialysis patients [1].
It has been shown that hyperglycemia play a signifi-
cant role on the development of microangiopathy, endo-
thelial dysfunction and on the inflammatory cytokines
production related to atherosclerosis [2]. Poor glycemic
control is associated with the development of comorbid-
ities such as coronary artery disease and myocardial in-
farction causing sudden cardiac death in the general* Correspondence: vraikou@med.uoa.gr
11st Department of Medicine - Propaedaetic, National and Kapodistrian University
of Athens, School of Medicine, 17 Agiou Thoma, Αthens, Greece
Full list of author information is available at the end of the article
© 2015 Raikou and Kyriaki; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.population [3]. Also, glycemia influences the electrolyte
balance, the function of potassium and calcium chan-
nels, and sympathetic activity resulting in arrhythmogen-
esis and sudden death particularly of patients in end
stage of renal disease (ESRD) [4].
However, it is not clear whether patients in the end
stage of renal disease (ESRD) with or/and without dia-
betes mellitus benefit from a strict glycemic control [5].
Few studies have been reported on the effect of intensive
glucose control in the later stages of chronic kidney dis-
ease [6]. Despite, it has been reported that intensive gly-
cemic control reduced the risk of microangiopathy in
both type 1 and 2 diabetes [7], previous trials evaluating
the effect of glucose control have provided conflicting
results on the rate of decrease in glomerular filtrationentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Outcomes Quality Initiative guidelines suggested that
lowering the glycated haemoglobin (HbA1c) level to
<7.0% might reduce the rate of decrease in renal func-
tion [8].On the other hand, in previous follow-up study
of the Action to Control Cardiovascular Risk in Diabetes
Study Group (ACCORD) trial, the outcome of ESRD
was not significantly different between the intensive and
standard glucose control groups [9].
In this study we focused on the relationship between
glycemic control defined by glucose serum concentra-
tions and insulin resistance, beta2M and markers of in-
flammation in patients undergoing maintenance dialysis
with or/and without diabetes mellitus.Methods
Patients
We studied 96 dialyzed patients at Nephrology Department
of “Laiko, University General Hospital of Athens” and Renal
Unit of “Diagnostic and Therapeutic Center of Athens
Hygeia SA”.62 males and 34 females participated in this
study, on mean age 62.1 ± 14.27 years old. Patients with ac-
tive infection, malignancy, glucocorticoid therapy or lym-
phoproliferative disease were excluded from our study.
The treatment modalities which were applied were :
regular hemodialysis (HD, n = 34), on-line- predilution
hemodiafiltration (on-l HDF, n = 42) and peritoneal dia-
lysis (PD, n = 20).The median time on hemodialysis was
5 years, interquartile range 3–10 years and the mean
time on peritoneal dialysis was 2.8 ± 1.61 years.
The hemodialysis treatment was performed 3-times
weekly with a dialysis time of 3.5-4 h per session, a filter of
1.5-2 m2 surface area and a blood flow of 350–400 ml/
min.A bicarbonate-based ultrapure buffer dialysis solution
was used with a dialysate flow rate of 500-600 ml/min, a
calcium concentration of 1.50-1.75mmol/L, a sodium con-
centration of 138-145mmol/L and low molecular weight
heparin as anticoagulant therapy.
We used exclusively high-flux synthetic dialysis mem-
brane, defined by a ultrafiltration coefficient >20 ml/h
[10].Dialysis dose was defined by Kt/V for urea, which was
calculated according to the formula of Daugirdas [11]. Pa-
tients were excluded if they had Kt/V for urea <1.2.
All patients on peritoneal dialysis were following con-
tinuous ambulatory peritoneal dialysis (CAPD) with 4
changes per day using a combination of 2 changes of 2 L
of hypertonic glucose-based solution (3.86% glucose; Bax-
ter Healthcare) and 2 changes of 2 L of semi-hypertonic
glucose solution (2.5% glucose; Ariti; Bieffe Medital
S.p.A.). Dialysis dose was defined by Kt/V/week for urea
in this group of patients and the patients, who had more
than 2 – 3 events of peritonitis per year, were excluded
from our study.20 hemodialyzed patients and 15 peritoneal dialyzed
patients excreted up to 100 ml of urine per day.None of
the enrolled patients was receiving hypolipidemic medi-
cines.Only calcium-free phosphate binders were pre-
scribed. The total of our subjects was on erythropoetin-a
or-β therapy.
The underlying renal disease was hypertensive nephro-
sclerosis (n = 31), chronic glomerulonephritis (n = 28),
polycystic kidney disease (n = 12), diabetic nephropathy
(n = 11), and other/unknown (n = 14).
Approval and consent
The study was approved by the ethics committee of the
Hospitals “Laiko, University General Hospital of Athens”
and Renal Unit of “Diagnostic and Therapeutic Center
of Athens Hygeia SA”.Written informed consent was ob-
tained from all subjects.
Blood collection
Blood samples were obtained by venipuncture in the
peritoneal dialyzed patients in a twelve hours fasting sta-
te.In hemodialyzed patients blood was drawn just before
the start of the mean weekly dialysis session also in a
twelve hours fasting state from the vascular access.In the
end of the treatment the blood pump speed was reduced
to <80 ml/min and blood samples was obtained at 2 min
post-dialysis from the arterial dialysis tubing for the calcu-
lation of the adequacy of dialysis by kt/V for urea. The
blood samples were centrifuged, and kept at a temperature
of −80° C.
In each subject, three sequences of samples were re-
ceived for the serum glucose measurements, and their
average was used for statistical analysis.
Laboratory measurments
Albumin and serum glucose concentrations were mea-
sured by biochemical analyzer (Architect, ci 16200,
Abbott).Hematocrit, hemoglobin and monocytes blood
cells values were measured by hematological analyzer
(Sysmex, xt-4000i, Roche).
The concentrations of beta2-microglobulin and insulin
were measured by radioimmunoassays (Immunotech by
Beckman, Czech Republic and BioSource Europe SA,
Belgium respectively).
Insulin resistance was calculated using the homeostasis
model assessment of insulin resistance (HOMA-IR) [12].
High sensitivity C-reactive protein (hsCRP) and serum
tumor necrosis factor-a (TNF-a) concentrations were
measured using enzyme linked immunoabsorbed assays
(ΕLISA, Immundiagnostik AG., Germany and Ani Bio-
tech Oy, Orgenium, Finland respectively) according to
manufacturer’s specifications.
Normalized protein catabolic rate for dry body mass
(nPCR) was calculated from the urea generation rate
Table 1 Characteristics of the studied population, n = 96 [Haemodialysis, HD, n = 76, Peritoneal dialysis, PD, n = 20
(62 males/34 females)]
Characteristic Minimum Maximum Mean/median SD/interquart range
Age (years) 24 87 62.10/ 14.27/
Haemodialysis duration (years) 0.5 27 /5.0 /3 - 10
Peritoneal dial duration (years) 1 6 2.8/ 1.61/
Body mass index (Kg/m2) 18.10 43.50 25.08/ 3.86/
Kt/V/day for HD patients (n = 76) 1.2 2.01 /1.29 /1.25 – 1.49
Kt/V/week for PD patients (n = 20) 1.7 2.58 2.14/ 0.27/
Normalized protein catabolic rate (nPCR, g/Kg/day) (n = 96) 0.97 3.41 2.23/ 0.616/
Urine volume (ml/day) 100 1500 337.35/ 305.8/
Serum bicarbonate levels (mmol/L ) 14.8 25.8 20.64/ 2.59/
beta2-microglobulin (mg/L) 8.29 138.0 /25.98 /16.1 – 32.7
hsCRP (mg/L) 0.12 21.35 8.65/ 5.9/
insulin (μU/ml) 3.16 110 /15.6 /11.3 – 29.8
ΗΟΜΑ-ΙR (mmol/L) 1.00 50.88 /3.6 /2.1 – 7.1
TNF-α (pg/ml) 0.10 170.4 /0.18 /0.0 – 31.0
Glucose (mg/dl) 60 201 97.7/ 26.6/
Albumin (gr/dl) 1.4 4.6 3.88/ 0.44/
Htc (%) 23.9 45.3 35.5/ 4.1/
Hemoglobin 7.97 15.1 11.8/ 1.37/
Monocytes (K/μl ) 0.10 1.20 0.53/ 0.23/ 1.08 .43
Table 2 Demographical characteristics of studied
patients, n = 96, (62 males/34 females)
Characteristic Valid percent
BMI > 25 43.4
Hypertension (yes) 32.3
Diabetes mellitus (yes) 11.5
Smoking (yes) 21.9
Left ventricular hypertrophy (yes) 56.3
Coronary disease (yes) 31.3
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post-dialysis body weight.
Metabolic acidosis was defined by serum bicarbonate
levels, which were measured using a blood gas analyzer
(Roche, cobas b 121 system) taking care of the blood
specimens [14].
Data analysis
Data was analyzed using SPSS 15.0 statistical package
for Windows (SPSS Inc, Chicago, Illinois) and expressed
as mean ± standard deviation or as median value ± inter-
quartile range for data that showed skewed distributions;
differences between mean values were assessed by using
paired-t test and Mann–Whitney U test. Correlations be-
tween variables were defined by Pearson and Spearman
coefficient and p values less than .05 were considered sig-
nificant. x2 analysis was used for the correlation between
categorical variables.We built a linear regression analysis
to investigate if glucose serum concentrations could be a
potential determinant of beta2M serum levels in dialysis
patients adjusting for age, gender, dialysis modality and
metabolic acidosis state.
Results
Characteristics and demographical characteristics of the
studied population at the time of inclusion are listed in
Tables 1 and 2.We divided the studied patients in two groups accord-
ing to serum glucose concentrations ( greater, n = 36 or
lower, n = 60 than 100mg/dl ).Comparing these groups
between them, we observed that the patients with higher
glucose concentrations (n = 36) had significantly in-
creased beta2M serum concentrations, insulin levels,
HOMA-IR and number of circulating blood monocytes
than the patients with lower serum glucose values (p <
0.05).BMI, hsCRP and TNF-α values were also greater in
patients with higher glucose concentrations (Table 3).
In total patients serum glucose was positively corre-
lated with beta2M (Figure 1), insulin, HOMA-IR, TNF-α
and monocytes (r = 0.320, p = 0.002, r = 0.558, p = 0.001,
r = 0.736, p = 0.001, r = 0.215, p = 0.03 and r = 0.302, p =
0.005 respectively).Beta2M was also positively associated
Table 3 Differences between groups of dialysis patients
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0.438, p = 0.001).
Additionally, x2 analysis showed significant association
between the patients with higher serum glucose concen-
trations and the patients with greater serum beta2Μ con-
centrations, using the median value of beta2M equal to
26mg/L, as dividing value (x2 = 4.44, p = 0.03) (Figure 2).
Linear regression analysis showed that glucose acts as
a significant independent determinant of beta2M serum
levels after adjustment for age, gender, dialysis modality
and metabolic acidosis state (Table 4).
Discussion
In present study, we observed a positive correlation be-
tween serum glucose consentrations and inflammatory
factors, as beta2M, TNF-α and circulating monocyte-
s.Additionally, the patients with higher serum glucose
had significantly higher beta2M serum concentrations,
insulin and insulin resistance values, as well asFigure 1 Positive correlation between glucose and beta2-microglobulin sesignificantly more circulating monocytes, than the pa-
tients with lower serum glucose concentrations. hsCRP
and TNF-α levels were also greater in higher glucose
group of patients.
It has been already reported that hyperglycemia up-
regulates inflammatory procedure by the excess gener-
ation of inflammatory cytokines and reactive free radi-
cals, causing oxidative stress [2]. Also, hyperglycemia
induces the production of the advanced glycation end
products (AGEs), which exert oxidative stress, or can be
a consequence of oxidative stress [15].These toxins are
profibrotic and directly involved in the pathogenesis of
the inflammatory response syndrome and in vascular
complications. In the meantime, the generation of ele-
vated AGEs during hyperglycemia modifies beta2M.
Beta2M , which has been increasingly investigated as a
diagnostic marker of kidney function, is accumulated in
the circulation of dialysis patients and its role on im-
munity and inflammation has been already reported
[16].In agreement, in present study we observed signifi-
cantly positive association between beta2M, circulating
monocytes and hsCRP. Also, AGE-modified beta2M
(AGE-beta2M) related to hyperglycemia may accelerate
the inflammatory procedure and may directly participate
in the pathobiology of amyloid formation in vessels wall
by stimulating chemotaxis of monocytes and synthesis of
cytokines from macrophages (interleukin-1β, TNF-α,
and interleukin-6) [17,18].
Another pathophysiological mechanism, which exerts
the oxidative stress and the increased production of
AGEs during hyperglycemia in this population of pa-
tients, is metabolic acidosis, which is a common condi-
tion particularly in end-stage renal disease patients [19].
Metabolic acidosis promotes inflammation releasing cy-
tokines and it is connected to many adverse effects ofrum concentrations (r = 0.320, p = 0.002).
Figure 2 Significant association between the patients with higher serum glucose concentrations (more than 100mg/dl) and the patients with
greater serum beta2-microglobulin concentrations (more than the median value of 26 mg/L) (x2 = 4.44, p = 0.03).
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creased insulin resistance and increased accumulation of
beta2Μ [20]. Maintenance dialysis therapies are often
unable to completely correct the base deficit.
Additionally, in this study using a multivariable model
we noted that glucose serum concentrations can be a
strong independent determinant of beta2M serum con-
centrations adjusting for age, gender, dialysis modality
related to dialysis adequacy and acidosis status.
Controversially to the findings of present study, previ-
ous study found no association between beta2M and
markers of diabetes mellitus, as glucose or glycated
hemoglobin (HbA1c), using a multivariate regression
model adjusting for age, gender and kidney function
(eGFR) in 1302 elderly healthy individuals, despite the
relationship of beta2M with CRP, systolic blood pressure,
total cholesterol and current smoking was found signifi-
cant [21].In dialysis patients special conditions perman-
ently hold, which are associated to up-regulation of
inflammatory microenvironment, as acidosis state andTable 4 Glucose as a potential independent determinant
of beta2-microglobulin serum concentrations in studied
dialyzed patients
Beta t Sig. Lower Upper
age −0,032 −0,258 0,797 −0,377 0,291
gender −0,1 −0,852 0,397 −13,318 5,355
Dialysis modality −0,017 −0,133 0,894 −11,524 10,082
Serum bicarbonate −0,024 −0,184 0,854 −2,088 1,736
glucose 0,361 3,04 0,003* 0,09 0,434
*: p < 0.05.oxidative stress, uremic toxicity, increased insulin resist-
ance and hypertension due to fluid overload [22,23].
These special conditions influence and are influenced by
hyperglycemia worsening its complications, thus hyper-
glycemia may be more hurtful in dialysis patients com-
paratively to healthy subjects, even though the studied
healthy subjects are on an old age.
On the other hand, the renal function in dialysis pa-
tients is exclusively represented by dialysis adequacy de-
fined by Kt/V for urea, related to following dialysis
modality, used dialysis membrane and duration of
hemodialysis session, in addition to the residual kidney
function, when it exists.Dialysis adequacy mainly regu-
lates beta2M serum concentrations in these patients, in
combination to the contribution of existing residual kid-
ney function [24], thus beta2M reflects the obtained dia-
lysis adequacy and serves as a surrogate marker of other
middle-molecules uremic toxins [25].Because of the ob-
tained dialysis adequacy is difficult to be equal to normal
renal function, beta2M values are commonly higher in
dialysis patients than in healthy subjects.
It could be suggested that a hurtful hyperglycemia, as
hyperglycemia in uremic and oxidative environment, can
determine the already elevated levels of beta2M, which,
in the meantime, is modified during hyperglycemia be-
coming more toxic and accelerating the inflammatory
procedure.This could be the explanation for the positive
association between glucose and beta2M explored in
present study, in opposite to the above reported previous
study, that studied elderly healthy subjects, whose the
conditions are absolutely different comparatively to dia-
lysis patients.
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that the elevated beta2M serum concentrations predis-
pose to a up-regulation of the inflammatory procedure,
which is associated with the increased glucose serum
concentrations in dialysis patients.On the other hand,
the elevated glucose serum concentrations were found
as a strong determinant of beta2M serum levels in dialy-
sis patients, thus a better glycemic control in combin-
ation to a better beta2M clearance obtained by a good
dialysis adequacy should be very beneficial for this popu-
lation of patients, resulting in down-regulation of
inflammation.
Conclusions
The elevated glucose concentrations were positively asso-
ciated with both, greater beta2M serum concentrations
and up-regulated inflammatory procedure in dialysis
patients with or/and without diabetes mellitus.
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